Table I.
Therapy of choice for children 8 years or younger with alopecia areata
| First-line |
Second-line |
|||||||
|---|---|---|---|---|---|---|---|---|
| <25% Scalp |
>25% Scalp |
<25% Scalp |
>25% Scalp |
|||||
| Fellowship trained | Nonfellowship trained | Fellowship trained | Nonfellowship trained | Fellowship trained | Nonfellowship trained | Fellowship trained | Nonfellowship trained | |
| Class 1 topical corticosteroids | 31 (79.5%) | 5 (35.7%)∗ | 26 (66.7%) | 7 (53.8%) | 5 (12.8%) | 2 (15.4%) | 2 (5.1%) | 4 (30.8%) |
| Class 2 topical corticosteroids | 11 (28.2%) | 6 (42.9%)∗ | 11 (28.2%) | 5 (38.5%) | 1 (2.6%) | 1 (7.7%) | 3 (7.7%) | 0 (0%) |
| Class 3 topical corticosteroids | 0 (0%) | 2 (14.3%) | 0 (0%) | 1 (7.7%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Class 4 topical corticosteroids | 1 (2.6%) | 1 (7.1%) | 0 (0%) | 1 (7.7%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Class 5 topical corticosteroids | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Topical anthralin | N/A | N/A | 2 (5.1%) | 1 (7.7%) | 6 (15.4%) | 3 (23.1%) | 5 (12.8%) | 4 (30.8%) |
| Topical calcineurin inhibitors | 3 (7.7%) | 1 (7.1%) | 2 (5.1%) | 1 (7.7%) | 3 (7.7%) | 1 (7.7%) | 4 (10.3%) | 1 (7.7%) |
| Topical immunotherapy (squaric acid, DCP, DNCB) | N/A | N/A | 5 (12.8%) | 1 (7.7%) | 9 (23.1%) | 5 (38.5%) | 13 (33.3%) | 4 (30.8%) |
| Intralesional triamcinolone | N/A | N/A | 2 (5.1%) | 3 (23.1%)∗ | 18 (46.2%) | 10 (76.9%)∗ | 3 (7.7%) | 3 (23.1%)∗ |
| Topical JAK inhibitors | N/A | N/A | 3 (7.7%) | 1 (7.7%) | 8 (20.5%) | 3 (23.1%) | 4 (10.3%) | 2 (15.4%) |
| Oral JAK inhibitors | N/A | N/A | 2 (5.1%) | 0 (0%) | 2 (5.1%) | 2 (15.4%) | 4 (10.3%) | 2 (15.4%) |
| Hydroxychloroquine | N/A | N/A | 2 (5.1%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (2.6%) | 0 (0%) |
| Topical minoxidil 2% solution | 5 (12.8%) | 1 (7.1%) | 3 (7.7%) | 1 (7.7%) | 2 (5.1%) | 1 (7.7%) | 4 (10.3%) | 2 (15.4%) |
| Topical minoxidil 5% solution | 6 (15.4%) | 3 (21.4%) | 9 (23.1%) | 4 (30.8%) | 10 (25.6%) | 4 (30.8%) | 8 (20.5%) | 7 (53.8%) |
| Excimer laser | N/A | N/A | 3 (7.7%) | 1 (7.7%) | 3 (7.7%) | 1 (7.7%) | 2 (5.1%) | 1 (7.7%) |
| Topical PUVA | N/A | N/A | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Oral PUVA | N/A | N/A | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Narrowband UVB | N/A | N/A | 0 (0%) | 0 (0%) | 1 (2.6%) | 0 (0%) | 2 (5.1%) | 0 (0%) |
| Oral steroids | N/A | N/A | 9 (23.1%) | 2 (15.4%) | 3 (7.7%) | 1 (7.7%) | 10 (25.6%) | 3 (23.1%) |
| Oral methotrexate | 1 (2.6%) | 0 (0%) | 5 (12.8%) | 0 (0%) | 2 (5.1%) | 0 (0%) | 15 (38.5%) | 2 (15.4%)∗ |
| None of the above | 1 (2.6%) | 0 (0%) | 0 (0%) | 0 (0%) | 2 (5.1%) | 0 (0%) | 1 (2.6%) | 0 (0%) |
| Other | 6 (15.4%) | 3 (21.4%) | 3 (7.7%) | 3 (23.1%) | 3 (7.7%) | 4 (30.8%) | 5 (12.8%) | 5 (38.5%) |
| Total | 39 | 14 | 39 | 13 | 39 | 13 | 39 | 13 |
DCP, Dipencyclopropenone; DNCB, dinitrochlorobenzene; PUVA, psoralens and ultraviolet A; UVB, ultraviolet B
∗
Statistically significant.